SUBSTANCE DEPENDENT TEENS--IMPACT OF TREATING DEPRESSION

物质依赖青少年——治疗抑郁症的影响

• 批准号: 6646416
• 负责人: Paula DeGraffenreid Riggs
• 金额: $ 65.75万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-30 至 2005-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6646416
• 关键词: adolescence (12-20); behavioral /social science research tag; clinical research; clinical trials; cognitive behavior therapy; combination therapy; comorbidity; conduct disorder; fluoxetine; human subject; human therapy evaluation; major depression; mental disorder chemotherapy; substance abuse related disorder; therapy compliance

DESCRIPTION: (Applicant's Abstract) Adolescents with substance use disorders (SUD) and conduct disorder (CD) have high rates of comorbid depression. Despite the high prevalence of depression in such youth, little is known about effective treatment of such depressions. Moreover, the effects of treating depression on substance use and other problem behaviors in such youth are not known. Only serotonergic agents, fluoxetine (FLX) and paroxetine, with most support for FLX, have empirical support in the treatment of depression in adolescents without serious comorbidity. It is not known whether FLX (or paroxetine) are effective in treating the depressions of adolescents with SUD and CD. The proposed study is a randomized, placebo-controlled trial comparing placebo to fluoxetine for major depressive disorder (MDD) in 120 adolescents with SUD and CD. Adolescents with DSM-1V SUD, CD, and MDD assessed both clinically and with structured assessment instruments, will be randomized to one of these two treatment cells for 16 weeks. All subjects will also receive standardized, manual-driven cognitive behavior treatment for adolescent SUD for the duration of the trial as the background "treatment as usual" Medication compliance will be electronically monitored. Adverse side effects will be monitored weekly. The specific aims of this study are to test the following hypotheses: 1. Fidoxeline + CBT will be more effective in treating unipolar depression in adolescents with SUD and CD than placebo + CBT. 2. The treatment of depression with RX + CBT, in depressed adolescents with SUD and CD will be more effective than placebo + CBT in reducing substance use and improving conduct symptoms. 3. The treatment of depression with RX will result in greater retention in, and compliance with substance treatment (CBT) and reduction in both substance use and conduct problems than treatment with placebo. This research will contribute important knowledge regarding effective treatment of depression in conduct-disordered adolescents with SUD and provide information about the effects of treating depression on substance and other behavioral outcomes as well.

描述：（申请人摘要） 患有物质使用障碍（SUD）和行为障碍（CD）的青少年 高比例的共病抑郁症尽管抑郁症的发病率很高， 这样的年轻人，很少有人知道如何有效地治疗这种抑郁症。 此外，治疗抑郁症对物质使用和其他问题的影响 这种年轻人的行为是未知的。仅限肾上腺素能药物，氟西汀 (FLX)和帕罗西汀，最支持FLX，有经验支持， 治疗无严重合并症的青少年抑郁症。不 已知FLX（或帕罗西汀）是否有效治疗抑郁症， 青少年SUD和CD。这项研究是一项随机的， 安慰剂与氟西汀治疗抑郁症的对照研究 在120名患有SUD和CD的青少年中，DSM-1V SUD青少年， 临床和结构化评估评估的CD和MDD 仪器，将随机分配到这两个处理单元之一， 周所有受试者还将接受标准化的手动认知测试。 在试验期间对青少年SUD进行行为治疗， 背景“照常治疗”药物依从性将以电子方式 监测。每周监测不良副作用。的具体目标 本研究拟验证以下假设：1. Fidoxeline + CBT将 更有效地治疗患有SUD和CD的青少年的单相抑郁症 安慰剂+ CBT。2. RX + CBT治疗抑郁症 SUD和CD青少年在以下方面比安慰剂+ CBT更有效： 减少物质使用并改善行为症状。3.治疗 RX抑郁症将导致更大的保留， 物质治疗（CBT）和减少物质使用和行为 比安慰剂治疗的问题。这项研究将有助于重要 关于有效治疗行为障碍性抑郁症的知识 青少年与SUD，并提供有关治疗效果的信息 抑郁症的物质和其他行为的结果，以及。